GlassScriptPhysician profile
Lydia E Lormand
NPI 1093072886
$1,993.24
in general payments reported to CMS, 2019-2025
25 companies · $207 in 2025
The $207 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $115 · 2021: $359 · 2022: $250 · 2023: $195 · 2024: $236 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $638.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $353.65 | 2019-2022 | |
| Astellas Pharma US INC | $254.51 | 2019-2024 | Veozah, Myrbetriq |
| Coopersurgical, INC. | $231.85 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Abbvie INC. | $152.51 | 2019-2022 | |
| Exeltis, USA INC. | $120.36 | 2019-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $103.07 | 2019-2023 | |
| Myovant Sciences INC. | $102.59 | 2021-2022 | |
| Pfizer INC. | $93.23 | 2021-2023 | |
| Vertical Pharmaceuticals, LLC | $67.95 | 2019 | |
| Aspira Women'S Health INC | $61.23 | 2024-2025 | Ova1 |
| Allergan, INC. | $50.90 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $50.55 | 2021-2023 | Gardasil 9 |
| Sage Therapeutics, LLC | $47.59 | 2025 | Zurzuvae |
| Covidien LP | $39.94 | 2019 | |
| Roche Diagnostics Corporation | $33.57 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $29.21 | 2023-2025 | Nexplanon |
| Lupin INC. | $29.03 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $28.28 | 2019-2020 | |
| Hologic Sales and Service, LLC | $24.24 | 2024 | Affirm Prone Biopsy System |
| Sumitomo Pharma America, INC. | $22.86 | 2025 | Myfembree |
| Genzyme Corporation | $21.81 | 2019 | |
| Smith+Nephew, INC. | $21.53 | 2019 | |
| Amgen INC. | $18.50 | 2020 | |
| Evofem Biosciences, INC. | $18.12 | 2021 | |
| Kci USA, INC. | $16.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lydia Lormand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.